Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. - Wikidata - wikimedia - TriplyDB

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

http://www.wikidata.org/entity/Q37422493

about

Oral paliperidone for schizophrenia Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability.A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia.Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.The pharmacology and formulation of paliperidone extended release.Paliperidone Palmitate-induced Urinary Incontinence: A Case Report.Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.

P2860

Q24242948-7DF4083D-F763-44D5-86C4-9A53EB0ADE7D Q35151598-1A8B53DD-FD4D-4116-B58A-955F72EB9F1E Q36628058-50572C9D-4850-44E0-8545-B28F9A960C6D Q36873906-A81AC0B2-82CC-4A8B-86BC-80D225752C0D Q37790388-EBA28CE1-6D87-48F6-824A-D306995ABCE9 Q38067139-C0622ECE-BC22-47A0-9AAF-1AE19F78C6F2 Q43063836-6948F9BF-8DAB-420A-A4C4-F2FABC36DCC9 Q50757787-C1894815-650B-4D2C-BAC6-698EB17735FC

P2860

Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

http://www.wikidata.org/entity/Q37422493

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Expected clinical benefits of ...... risperidone immediate-release.

@en

Expected clinical benefits of ...... risperidone immediate-release.

@nl

type

label

Expected clinical benefits of ...... risperidone immediate-release.

@en

Expected clinical benefits of ...... risperidone immediate-release.

@nl

prefLabel

Expected clinical benefits of ...... risperidone immediate-release.

@en

Expected clinical benefits of ...... risperidone immediate-release.

@nl

P1433

Q37422493-41D7CCE7-C620-43AD-B578-81733C8B1DAB

P1476

Q37422493-64C552DE-5CCC-4B0E-B048-6F8CEBA40C34

P2093

Q37422493-6EBA0D50-B2B1-433F-890E-59A3ECA58B3D

P2860

Q37422493-071BC91F-CCE4-4DD8-B069-8FEC1014AA8D

Q37422493-0B9A1913-2942-492C-9C00-E028ED230784

Q37422493-0C0CBD13-E9B6-4C7A-9406-5FBDED7BE45B

Q37422493-155D444C-8432-4EE5-A45C-24716D126B1B

Q37422493-155DB048-4182-4504-B814-73FF3C2CEC6D

Q37422493-172DEA12-4939-4612-9B02-001D744F85B2

Q37422493-1837927A-AE2E-40DC-9B4A-3733EDFBCCD1

Q37422493-18E74E6D-2CDE-4C86-8575-BEC9077AE886

Q37422493-232B4952-44F8-46CA-BE14-30EC24080EDD

Q37422493-266F6B5E-6B93-4928-A4E7-EC595CB4DD20

P304

Q37422493-467FC881-709B-4651-84DA-DAAF5CF257CD

P31

Q37422493-FDE6651D-3A6B-4162-A8E7-657E70F0EF62

P356

Q37422493-FFD04B97-8BF7-43AC-A240-8FD9D9F9EAF9

P407

Q37422493-03D7690F-6335-4369-9338-41D3CFC9909A

P433

Q37422493-EDE1048F-0674-4623-BB71-B4A0D72FC529

P478

Q37422493-E8BF26C4-AC51-4129-AE51-2CBA480BB790

P50

Q37422493-56ADF644-63AB-46B3-A656-9BAEED48066D

P577

Q37422493-C3F54FCC-F265-409C-8E6E-E15C09735632

P698

Q37422493-21F56A2D-ABA4-45BB-B0FE-F1429804EF1C

P356

17425240902780158

P1433

Expert Opinion on Drug Delivery

P1476

Expected clinical benefits of ...... risperidone immediate-release

@en

P2093

Giorgio Marchese

http://www.w3.org/2001/XMLSchema#string

P2860

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

Gastrointestinal Safety of an Extended-Release, Nondeformable, Oral Dosage Form (OROS??)*

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.

Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.

P304

319-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425240902780158

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19317589

http://www.w3.org/2001/XMLSchema#string